{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-104392","form_type":"8-K","ticker":"CCEL","cik":"0000862692","company_name":"CRYO CELL INTERNATIONAL INC","filed_at":"2026-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.844572+00:00","generated_at":"2026-05-15T14:33:39.878653+00:00","sec_items":["3.01","7.01","9.01"],"event_type":"regulatory","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Cryo-Cell receives NYSE American delisting notice over stockholders' deficit and net losses","bullets":["NYSE American cited stockholders' deficit as of Nov 30, 2025 and net losses in two of three fiscal years ended Nov 30, 2025.","Company must submit compliance plan by April 8, 2026; if accepted, extension up to 18 months possible.","Trading of CCEL common stock continues on NYSE American while company pursues compliance plan.","No assurance that plan will be accepted or that compliance can be regained; delisting possible if not."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-104392","json":"https://secwatch.observer/filing/0001193125-26-104392.json","markdown":"https://secwatch.observer/filing/0001193125-26-104392.md","text":"https://secwatch.observer/filing/0001193125-26-104392.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/862692/000119312526104392/0001193125-26-104392-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/862692/000119312526104392/ccel-20260309.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T14:33:39.878653+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"7d73500704e9b89c8e9b700426bfebe8d7cfc97f","claim":"CRYO CELL INTERNATIONAL INC received a nyse_american deficiency notice notice regarding stockholders equity (rules 1003(a)).","evidence_excerpt":"March 9, 2026, Cryo-Cell International, Inc. (“Cryo-Cell”) received a written notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating that the Company is not in compliance with the continued listing standards set forth in Section 1003 (a) of the NYSE American Company Guide. The Notice has no immediate effect on the listing or trading of the Company’s common stock, which will continue to trade on the NYSE American under the symbol “CCEL” while the Company pursues a plan to regain compliance.  In accordance with NYSE American procedures, the Company intends to submit a plan of","evidence_source":"SEC 8-K Item 3.01","evidence_url":"https://www.sec.gov/Archives/edgar/data/862692/000119312526104392/0001193125-26-104392-index.htm","confidence":0.95}],"comparable_filings":[{"accession":"0001213900-26-062935","ticker":"ATNM","company_name":"Actinium Pharmaceuticals, Inc.","filed_at":"2026-05-29T21:10:41+00:00","headline":"Actinium receives NYSE American non-compliance notice for low stockholders' equity; must submit plan by June 26","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-062935","json":"https://secwatch.observer/filing/0001213900-26-062935.json","markdown":"https://secwatch.observer/filing/0001213900-26-062935.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1388320/000121390026062935/0001213900-26-062935-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1388320/000121390026062935/ea0292691-8k_actinium.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"March 9, 2026, Cryo-Cell International, Inc. (“Cryo-Cell”) received a written notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating that the Company is not in compliance with the continued listing standards set forth in Section 1003 (a) of the NYSE American Company Guide. The Notice has no immediate effect on the listing or trading of the Company’s common stock, which will continue to trade on the NYSE American under the symbol “CCEL” while the Company pursues a plan to regain compliance.  In accordance with NYSE American procedures, the Company intends to submit a plan of","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/862692/000119312526104392/0001193125-26-104392-index.htm","comparable_excerpt":"May 27, 2026, Actinium Pharmaceuticals, Inc.\n(the “Company”) received a notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating\nthat the Company is not in compliance with the continued listing standards set forth in Section 1003(a)(ii) of the NYSE American Company\nGuide (the “Company Guide”), which requires a listed company to maintain stockholders’ equity of $4.0 million or more\nif it has reported losses from continuing operations and/or net losses in three of its four most recent fiscal years. As of March 31,\n2026, the Company reported stockholders’ equity of approximately","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1388320/000121390026062935/0001213900-26-062935-index.htm"}},{"accession":"0001493152-26-025629","ticker":"CDT","company_name":"CDT Equity Inc.","filed_at":"2026-05-28T20:30:30+00:00","headline":"CDT Equity receives Nasdaq deficiency letter for late Q1 10-Q filing; has until July 20 to submit plan","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-025629","json":"https://secwatch.observer/filing/0001493152-26-025629.json","markdown":"https://secwatch.observer/filing/0001493152-26-025629.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1896212/000149315226025629/0001493152-26-025629-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1896212/000149315226025629/form8-k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"March 9, 2026, Cryo-Cell International, Inc. (“Cryo-Cell”) received a written notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating that the Company is not in compliance with the continued listing standards set forth in Section 1003 (a) of the NYSE American Company Guide. The Notice has no immediate effect on the listing or trading of the Company’s common stock, which will continue to trade on the NYSE American under the symbol “CCEL” while the Company pursues a plan to regain compliance.  In accordance with NYSE American procedures, the Company intends to submit a plan of","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/862692/000119312526104392/0001193125-26-104392-index.htm","comparable_excerpt":"May 21, 2026, CDT Equity Inc. (the “Company”) received a deficiency letter (the “Notice”) from the Nasdaq Listing\nQualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it was not in compliance with\nNasdaq Listing Rule 5250(c)(1) (the “Periodic Filing Requirement”) because the Company did not file its Quarterly Report\non Form 10-Q for the three-month period ended March 31, 2026 (the “Form 10-Q”) in a timely manner, as required for continued\nlisting on The Nasdaq Capital Market. The Notice has no immediate effect on the listing or trading of the Company’s","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1896212/000149315226025629/0001493152-26-025629-index.htm"}},{"accession":"0001213900-26-061545","ticker":"CHAR","company_name":"Charlton Aria Acquisition Corp","filed_at":"2026-05-27T20:41:44+00:00","headline":"Charlton Aria receives Nasdaq delinquency notice for untimely Q1 10-Q filing","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.7,"calibrated_materiality_score":0.7,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-061545","json":"https://secwatch.observer/filing/0001213900-26-061545.json","markdown":"https://secwatch.observer/filing/0001213900-26-061545.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/2024459/000121390026061545/0001213900-26-061545-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2024459/000121390026061545/ea0292193-8k_charlton.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"March 9, 2026, Cryo-Cell International, Inc. (“Cryo-Cell”) received a written notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating that the Company is not in compliance with the continued listing standards set forth in Section 1003 (a) of the NYSE American Company Guide. The Notice has no immediate effect on the listing or trading of the Company’s common stock, which will continue to trade on the NYSE American under the symbol “CCEL” while the Company pursues a plan to regain compliance.  In accordance with NYSE American procedures, the Company intends to submit a plan of","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/862692/000119312526104392/0001193125-26-104392-index.htm","comparable_excerpt":"May 22, 2026, Charlton\nAria Acquisition Corporation (the “ Company ”) received a letter (the “ Notice ”) from the Listing Qualifications\nDepartment of The Nasdaq Stock Market LLC (“ Nasdaq ”), notifying the Company that","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/2024459/000121390026061545/0001213900-26-061545-index.htm"}},{"accession":"0001493152-26-025277","ticker":"VSTD","company_name":"Vestand Inc.","filed_at":"2026-05-26T21:18:59+00:00","headline":"Vestand receives Nasdaq delisting notice for late quarterly and annual filings","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-025277","json":"https://secwatch.observer/filing/0001493152-26-025277.json","markdown":"https://secwatch.observer/filing/0001493152-26-025277.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1898604/000149315226025277/0001493152-26-025277-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1898604/000149315226025277/form8-k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"March 9, 2026, Cryo-Cell International, Inc. (“Cryo-Cell”) received a written notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating that the Company is not in compliance with the continued listing standards set forth in Section 1003 (a) of the NYSE American Company Guide. The Notice has no immediate effect on the listing or trading of the Company’s common stock, which will continue to trade on the NYSE American under the symbol “CCEL” while the Company pursues a plan to regain compliance.  In accordance with NYSE American procedures, the Company intends to submit a plan of","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/862692/000119312526104392/0001193125-26-104392-index.htm","comparable_excerpt":"May 19, 2026, the Company received a Staff Delisting Determination letter (the “Staff Determination”) from Nasdaq notifying\nit that Nasdaq has initiated a process which could result in the delisting of the Company’s secu","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1898604/000149315226025277/0001493152-26-025277-index.htm"}},{"accession":"0001836875-26-000036","ticker":"NVVE","company_name":"Nuvve Holding Corp.","filed_at":"2026-05-22T22:35:13+00:00","headline":"Nuvve receives Nasdaq delisting notice for late Q1 10-Q filing; already under $1.00 bid price review","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.75,"calibrated_materiality_score":0.75,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001836875-26-000036","json":"https://secwatch.observer/filing/0001836875-26-000036.json","markdown":"https://secwatch.observer/filing/0001836875-26-000036.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1836875/000183687526000036/0001836875-26-000036-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1836875/000183687526000036/nvve-20260522.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"March 9, 2026, Cryo-Cell International, Inc. (“Cryo-Cell”) received a written notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating that the Company is not in compliance with the continued listing standards set forth in Section 1003 (a) of the NYSE American Company Guide. The Notice has no immediate effect on the listing or trading of the Company’s common stock, which will continue to trade on the NYSE American under the symbol “CCEL” while the Company pursues a plan to regain compliance.  In accordance with NYSE American procedures, the Company intends to submit a plan of","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/862692/000119312526104392/0001193125-26-104392-index.htm","comparable_excerpt":"May 22, 2026, Nuvve Holding Corp. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, since the Company","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1836875/000183687526000036/0001836875-26-000036-index.htm"}},{"accession":"0001213900-26-054565","ticker":"AGAE","company_name":"Allied Gaming & Entertainment Inc.","filed_at":"2026-05-11T21:09:36+00:00","headline":"AGAE receives Nasdaq delisting notice over bid price <$1.00 and late 10-K; will appeal","event_type":"regulatory","sec_items":["3.01","5.03","7.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-054565","json":"https://secwatch.observer/filing/0001213900-26-054565.json","markdown":"https://secwatch.observer/filing/0001213900-26-054565.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1708341/000121390026054565/0001213900-26-054565-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1708341/000121390026054565/ea0290063-8k_allied.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"March 9, 2026, Cryo-Cell International, Inc. (“Cryo-Cell”) received a written notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating that the Company is not in compliance with the continued listing standards set forth in Section 1003 (a) of the NYSE American Company Guide. The Notice has no immediate effect on the listing or trading of the Company’s common stock, which will continue to trade on the NYSE American under the symbol “CCEL” while the Company pursues a plan to regain compliance.  In accordance with NYSE American procedures, the Company intends to submit a plan of","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/862692/000119312526104392/0001193125-26-104392-index.htm","comparable_excerpt":"termination\nbefore an independent Hearings Panel (the “Panel”) by May 13, 2026. On November 4, 2025, Staff notified the Company\nthat the bid price of the Common Stock had closed at less than $1.00 per share over 30 consecutive business days, and, as a result, did\nnot comply with Nasdaq Listing Rule 5550(a)(2) (the “Minimum Bid Price Rule”). The Staff Determination was issued pursuant\nto Nasdaq Listing Rule 5810(c)(3)(A) on the grounds that the Company has not regained compliance with the Minimum Bid Price Rule during\na 180-day compliance period and is not eligible for a second 180-day complian","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1708341/000121390026054565/0001213900-26-054565-index.htm"}},{"accession":"0001731122-26-000668","ticker":"SBEV","company_name":"SPLASH BEVERAGE GROUP, INC.","filed_at":"2026-05-05T23:59:59+00:00","headline":"Splash Beverage receives NYSE delisting notice; shareholders' equity negative $15.3M","event_type":"regulatory","sec_items":["1.01","1.02","3.01","3.02","5.03","7.01","9.01"],"materiality_score":0.85,"calibrated_materiality_score":0.85,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001731122-26-000668","json":"https://secwatch.observer/filing/0001731122-26-000668.json","markdown":"https://secwatch.observer/filing/0001731122-26-000668.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1553788/000173112226000668/0001731122-26-000668-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1553788/000173112226000668/e7604_8-k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"March 9, 2026, Cryo-Cell International, Inc. (“Cryo-Cell”) received a written notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating that the Company is not in compliance with the continued listing standards set forth in Section 1003 (a) of the NYSE American Company Guide. The Notice has no immediate effect on the listing or trading of the Company’s common stock, which will continue to trade on the NYSE American under the symbol “CCEL” while the Company pursues a plan to regain compliance.  In accordance with NYSE American procedures, the Company intends to submit a plan of","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/862692/000119312526104392/0001193125-26-104392-index.htm","comparable_excerpt":"April 29, 2026, the Company received notice from NYSE Regulation (the “NYSE”)\nthat the Company is not in compliance with the shareholders’ equity requirement of $6 million as of December 31, 2025 as outlined\nin Section 1","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1553788/000173112226000668/0001731122-26-000668-index.htm"}},{"accession":"0001493152-26-019609","ticker":"VSTD","company_name":"Vestand Inc.","filed_at":"2026-04-29T23:59:59+00:00","headline":"Vestand receives Nasdaq delisting notice for late 10-K filing; may submit compliance plan by May 18, 2026","event_type":"regulatory","sec_items":["3.01","7.01","9.01"],"materiality_score":0.8,"calibrated_materiality_score":0.8,"match_reasons":["same fact type: exchange_compliance_notice","same SEC item: 3.01, 7.01, 9.01","same event type: regulatory","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-019609","json":"https://secwatch.observer/filing/0001493152-26-019609.json","markdown":"https://secwatch.observer/filing/0001493152-26-019609.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1898604/000149315226019609/0001493152-26-019609-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1898604/000149315226019609/form8-k.htm"},"side_by_side_evidence":{"fact_type":"exchange_compliance_notice","source_excerpt":"March 9, 2026, Cryo-Cell International, Inc. (“Cryo-Cell”) received a written notice (the “Notice”) from NYSE American LLC (“NYSE American”) indicating that the Company is not in compliance with the continued listing standards set forth in Section 1003 (a) of the NYSE American Company Guide. The Notice has no immediate effect on the listing or trading of the Company’s common stock, which will continue to trade on the NYSE American under the symbol “CCEL” while the Company pursues a plan to regain compliance.  In accordance with NYSE American procedures, the Company intends to submit a plan of","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/862692/000119312526104392/0001193125-26-104392-index.htm","comparable_excerpt":"April 23, 2026, Vestand Inc. (the “Company”) received a staff deficiency notice (the “Notice”) from The Nasdaq\nStock Market (“Nasdaq”) indicating that, because Nasdaq has not yet received the Company’s Form 10-K for the","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1898604/000149315226019609/0001493152-26-019609-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}